1. Summary (Limit your answer in 300 words only). 10 points
This article examines Streptomyces sp.'s potential as a source of antibacterial substances to prevent the
growth of biofilm on biomedical devices. On implantable medical devices, biofilms are frequent and can
cause infections that are challenging to treat with standard antibiotics due to bacterial resistance.
Among the bacteria that create biofilms, Methicillin-Resistant Staphylococcus aureus (MRSA) is the most
concerning. According to the authors, Streptomyces sp. can generate secondary metabolites with MRSA
biofilm-targeting antibacterial action. These substances have the ability to prevent the growth of
biofilms, destroy already-formed biofilms, and improve the effectiveness of antimicrobial agents. In
addition, these substances are less harmful than traditional antibiotics and can lessen the emergence of
bacterial resistance. The article provides examples of chemicals produced from Streptomyces with
notable antibacterial action against MRSA biofilm are highlighted in the article. One new cyclic peptide,
icosalide A, discovered from Streptomyces sp., has demonstrated strong action against MRSA biofilms.
Streptomyces sp. produces the macrolide antibiotic fidaxomicin, another substance that exhibits
promising efficacy against MRSA planktonic cells. The researchers claim that Streptomyces sp. could be
used as a natural source of substances with antibacterial properties that can successfully prevent MRSA
biofilm formation on biomedical devices. This study offers a potential alternate strategy to treat and
prevent illnesses connected to biofilms, which is important given the growing concern about antibiotic
resistance. the discovery of fresh, powerful substances from uncultivated sources like Streptomyces sp.
emphasizes the value of searching the vast natural reservoir for novel antibiotics. This study paves the
way for further research and development of Streptomyces-derived compounds as next-generation
biomedical devices coatings.
2. Reaction (Limit your answer in 800 words only). 20 points
Antibiotic resistance in bacteria has grown to be a significant problem for the healthcare sector. It is
challenging to treat infections due to the emergence of novel bacterial strains caused by the overuse of
antibiotics, which are resistant to conventional antibiotics. Methicillin-Resistant Staphylococcus aureus
(MRSA), a major contributor to hospital-acquired infections, is one of the most challenging bacteria.
MRSA is especially dangerous because it builds biofilms on biomedical equipment, which makes it
challenging to get rid of and raises the risk of infection. The potential of Streptomyces sp. is discussed by
the writers in this publication. as a supply of fresh chemicals to battle biofilms on biomedical equipment.
Infection with Streptomyces sp. is a group of bacteria that produces a variety of bioactive substances,
such as antibiotics and anticancer drugs. According to the scientists, these substances may be utilized to
treat infections caused by biofilms and may also pave the way for the creation of brand-new
medications. The authors reviewed the literature on the use of Streptomyces sp. for treating biofilm-
associated infections. They found that several Streptomyces sp. strains have been shown to have
antibacterial activity against MRSA biofilms. For example, Streptomyces coelicolor has been shown to
produce an enzyme that degrades the extracellular polymeric substance (EPS) that makes up the biofilm.
This allows other antibiotics to penetrate the biofilm and kill the bacteria. In addition, Streptomyces sp.
strains have been shown to produce substances that disrupt the formation of biofilms. For example,
Streptomyces sp. strain S252 has been shown to produce a compound called congocidine, which inhibits
the formation of MRSA biofilms. Other compounds produced by Streptomyces sp. have been shown to
interfere with quorum sensing, which is the communication mechanism used by bacteria to coordinate
the formation of biofilms. There are several challenges associated with using Streptomyces sp.
compounds for treating biofilm-associated infections. For example, the compounds produced by
This article examines Streptomyces sp.'s potential as a source of antibacterial substances to prevent the
growth of biofilm on biomedical devices. On implantable medical devices, biofilms are frequent and can
cause infections that are challenging to treat with standard antibiotics due to bacterial resistance.
Among the bacteria that create biofilms, Methicillin-Resistant Staphylococcus aureus (MRSA) is the most
concerning. According to the authors, Streptomyces sp. can generate secondary metabolites with MRSA
biofilm-targeting antibacterial action. These substances have the ability to prevent the growth of
biofilms, destroy already-formed biofilms, and improve the effectiveness of antimicrobial agents. In
addition, these substances are less harmful than traditional antibiotics and can lessen the emergence of
bacterial resistance. The article provides examples of chemicals produced from Streptomyces with
notable antibacterial action against MRSA biofilm are highlighted in the article. One new cyclic peptide,
icosalide A, discovered from Streptomyces sp., has demonstrated strong action against MRSA biofilms.
Streptomyces sp. produces the macrolide antibiotic fidaxomicin, another substance that exhibits
promising efficacy against MRSA planktonic cells. The researchers claim that Streptomyces sp. could be
used as a natural source of substances with antibacterial properties that can successfully prevent MRSA
biofilm formation on biomedical devices. This study offers a potential alternate strategy to treat and
prevent illnesses connected to biofilms, which is important given the growing concern about antibiotic
resistance. the discovery of fresh, powerful substances from uncultivated sources like Streptomyces sp.
emphasizes the value of searching the vast natural reservoir for novel antibiotics. This study paves the
way for further research and development of Streptomyces-derived compounds as next-generation
biomedical devices coatings.
2. Reaction (Limit your answer in 800 words only). 20 points
Antibiotic resistance in bacteria has grown to be a significant problem for the healthcare sector. It is
challenging to treat infections due to the emergence of novel bacterial strains caused by the overuse of
antibiotics, which are resistant to conventional antibiotics. Methicillin-Resistant Staphylococcus aureus
(MRSA), a major contributor to hospital-acquired infections, is one of the most challenging bacteria.
MRSA is especially dangerous because it builds biofilms on biomedical equipment, which makes it
challenging to get rid of and raises the risk of infection. The potential of Streptomyces sp. is discussed by
the writers in this publication. as a supply of fresh chemicals to battle biofilms on biomedical equipment.
Infection with Streptomyces sp. is a group of bacteria that produces a variety of bioactive substances,
such as antibiotics and anticancer drugs. According to the scientists, these substances may be utilized to
treat infections caused by biofilms and may also pave the way for the creation of brand-new
medications. The authors reviewed the literature on the use of Streptomyces sp. for treating biofilm-
associated infections. They found that several Streptomyces sp. strains have been shown to have
antibacterial activity against MRSA biofilms. For example, Streptomyces coelicolor has been shown to
produce an enzyme that degrades the extracellular polymeric substance (EPS) that makes up the biofilm.
This allows other antibiotics to penetrate the biofilm and kill the bacteria. In addition, Streptomyces sp.
strains have been shown to produce substances that disrupt the formation of biofilms. For example,
Streptomyces sp. strain S252 has been shown to produce a compound called congocidine, which inhibits
the formation of MRSA biofilms. Other compounds produced by Streptomyces sp. have been shown to
interfere with quorum sensing, which is the communication mechanism used by bacteria to coordinate
the formation of biofilms. There are several challenges associated with using Streptomyces sp.
compounds for treating biofilm-associated infections. For example, the compounds produced by
